Patent ID: 8333970
Filing Date: 2012-12-18
Classification: A61P,G01N

Abstract:
1. A method for identifying a subject having an inflammatory disease or autoimmune disease that is responsive to treatment with an anti-CD40 therapeutic agent, said method comprising: a) providing a test biological sample obtained from said subject and a control biological sample obtained from said subject, wherein said test biological sample and said control biological sample comprise CD40-expressing cells that have been stimulated with a CD40 ligand; b) contacting said test biological sample with an effective amount of said anti-CD40 therapeutic agent; c) detecting the level of at least one biomarker in said test biological sample, wherein said biomarker is selected from the group consisting of: d) comparing the level of said at least one biomarker in said test biological sample to the level of said at least one biomarker detected in said control biological sample, wherein said control biological sample has not been contacted with said anti-CD40 therapeutic agent, wherein (iii) at least a 25% reduction in the level of at least one of said biomarkers of cell survival in said test biological sample relative to said control biological sample is indicative of a subject who would benefit from treatment with said anti-CD40 therapeutic agent; wherein said anti-CD40 therapeutic agent is an antagonist anti-CD40 monoclonal antibody that is capable of specifically binding to a human CD40 antigen expressed on the surface of a human B cell, said monoclonal antibody being free of significant agonist activity when bound to the CD40 antigen expressed on the surface of said B cell, wherein said anti-CD40 monoclonal antibody is selected from the group consisting of: